QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its...

QuantuMDx partners with Cignpost Diagnostics QuantuMDx partners with Cignpost Diagnostics Providing a rapid, PCR COVID-19 testing solution to the UK film & TV industry NEWCASTLE UPON TYNE, UK, 16 August 2021. QuantuMDx Group Limited has...

QuantuMDx launches Q-POC™ - rapid PCR point of care diagnostic system QuantuMDx launches Q-POC™ - rapid PCR point of care diagnostic system Roll out at ECCMID 2021 with Q-POC™ SARS-CoV-2 assay96.9% sensitivity, 98.3% specificitySample to result - approximately 30...

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx                     -          QuantuMDx has developed Q-POC™ - a rapid, PCR diagnostic device for coronavirus testing at the point of...

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C&GT”s), to be evaluated by GlaxoSmithKline’s C&GT platform group. Press Release: 17 April 2019 QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies...